Yayın:
Design, synthesis and biological evaluation of a new series of imidazothiazole-hydrazone hybrids as dual EGFR and Akt inhibitors for NSCLC therapy

Sadeleştirilmiş öğe sayfası
dc.contributor.authorALTINTOP, MEHLİKA DİLEK
dc.contributor.authorErtorun, İpek
dc.contributor.authorÇiftçi, Gülşen Akalın
dc.contributor.authorÖZDEMİR, AHMET
dc.contributor.orcid0000-0002-8159-663X
dc.contributor.orcid0000-0001-8328-4157
dc.contributor.orcid0000-0001-5098-8967
dc.contributor.orcid0000-0003-0280-5550
dc.date.accessioned2025-11-13T09:50:12Z
dc.date.issued2024-07-20
dc.identifier.doihttps://doi.org/10.1016/j.ejmech.2024.116698
dc.identifier.endpage116698
dc.identifier.issn0223-5234
dc.identifier.openalexW4400852618
dc.identifier.startpage116698
dc.identifier.urihttps://hdl.handle.net/11421/2337
dc.identifier.urihttps://doi.org/10.1016/j.ejmech.2024.116698
dc.identifier.volume276
dc.language.isoen
dc.relation.ispartofEuropean Journal of Medicinal Chemistry
dc.rightsopenAccess
dc.subjectChemistry
dc.subjectHydrazone
dc.subjectDual (grammatical number)
dc.subjectProtein kinase B
dc.subjectSeries (stratigraphy)
dc.subjectHybrid
dc.subjectPharmacology
dc.subjectStereochemistry
dc.subjectPhosphorylation
dc.subjectBiochemistry
dc.subjectBotany
dc.subjectBiology
dc.titleDesign, synthesis and biological evaluation of a new series of imidazothiazole-hydrazone hybrids as dual EGFR and Akt inhibitors for NSCLC therapy
dc.typeArticle
dspace.entity.typePublication
local.authorid.openalexA5048968214
local.authorid.openalexA5035115463
local.authorid.openalexA5045943806
local.authorid.openalexA5100651829

Dosyalar

Koleksiyonlar

Publications